Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Accumulated Expenses (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Accumulated Expenses for 7 consecutive years, with $11.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 37.73% year-over-year to $11.0 million, compared with a TTM value of $11.0 million through Sep 2025, up 37.73%, and an annual FY2024 reading of $12.0 million, up 36.37% over the prior year.
  • Accumulated Expenses was $11.0 million for Q3 2025 at Summit Therapeutics, up from $6.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $21.2 million in Q1 2025 and bottomed at $1.5 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $7.8 million, with a median of $6.6 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses tumbled 69.2% in 2022, then surged 712.68% in 2023.
  • Year by year, Accumulated Expenses stood at $7.2 million in 2021, then fell by 21.62% to $5.6 million in 2022, then skyrocketed by 55.7% to $8.8 million in 2023, then soared by 36.37% to $12.0 million in 2024, then dropped by 8.45% to $11.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for SMMT at $11.0 million in Q3 2025, $6.6 million in Q2 2025, and $21.2 million in Q1 2025.